PDCD1 and colorectal carcinoma: Recently, favorable outcomes have been reported in clinical trials with anti-programmed cell death protein-1 (anti-PD1) checkpoint therapy in microsatellite-instability—high (MSI-H) CRC, but with limited success in microsatellite-stable (MSS) CRC disease, which represents ~85% of CRC23–25.